Kannan Rangaramanujam | AIChE

Kannan Rangaramanujam

Johns Hopkins School of Medicine

Dr. Kannan Rangaramanujam is the Arnall Patz distinguished professor of ophthalmology and co-director of center for nanomedicine at the Wilmer Eye Institute at Johns Hopkins School of Medicine. He has joint/courtesy appointments in Chemical and Biomolecular Engineering, and Materials Science and Engineering at Johns Hopkins. He is also a research scientist at the Kennedy-Krieger Institute. He obtained his PhD in Chemical Engineering from the California Institute of Technology, and followed it with a post-doc from the University of Minnesota. His research interested are in the field of translational nanomedicine, focused on targeted therapies for neuroinflammation, based on a dendrimer platform. He has initiated an interdisciplinary translational research program based on dendrimers, with a specific focus on systemic, targeted drug delivery strategies for treating neuroinflammation, in a variety of central nervous system and ocular disorders. Dr. Kannan is an author of many patents (issued and pending, licensed), more than 85 peer-reviewed publications. He has won several recognitions, including the NSF CAREER and Unilever awards. His research is primarily funded by NIH. He is the co-founder and chief technology officer of Ashvattha Therapeutics and Orpheris Inc., two spinoffs that are translating his team’s patented dendrimer technologies.